Intellectual Property

Q-Sera’s technology is based on research from the University of Queensland and is patent protected to 2035.

Family 1 Protection to Sept 2031

'Serum Preparation'

This patent covers all prothrombin activators from snake venom including naturally occurring and recombinant versions in blood collection tubes for the production of serum for biochemical analysis.

Patent granted or allowed in US, EU, Japan, China, Canada, Mexico, Russia, South Korea, South Africa, Australia, Israel, Brazil and India.

Family 2 Additional protection to Oct 2035

'Improved Clotting Composition'

Covers formulations to enhance the temperature and irradiation stability of snake venom prothrombin activators in blood collection tubes.

Patent granted or allowed in US, Japan, Australia, South Africa and China.
Patent pending in EU, and Canada